2026 Key Intermediate Campaigns
Division II annual focus list · organised by target drug · with key fragments and public milestones
Focus Projects4 target drugs · 7 key intermediates
Ordered by downstream commercial certainty; open one for its fragment list and milestonesLenacapavir
A twice-yearly HIV prevention and treatment agent — three fluorine / boron key fragments supplied as a package
HIV-1 capsid inhibitor acting at multiple stages of the viral lifecycle
Orforglipron
The oral GLP-1 weight-loss candidate — two chiral indole fragments, capacity prepared ahead of launch
Oral small-molecule GLP-1 receptor agonist (non-peptide)
Inavolisib
A PI3Kα-targeted breast cancer drug — the chiral difluoromethyl oxazolidinone building block
Selective PI3Kα inhibitor that also drives degradation of mutant PI3Kα
Osilodrostat
An orphan drug for Cushing's syndrome — the imidazole acetic acid backbone on routine supply
11β-hydroxylase (CYP11B1) inhibitor blocking the final step of cortisol synthesis
Full list of campaign intermediatesCAS numbers link through to the patent-cliff intermediate dossier; enquiries go straight to sourcing
CAS 7| CAS No. | Chemical name | Fragment role | Target drug | Action |
|---|---|---|---|---|
| 2189684-53-3 | 4-Chloro-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indazol-3-amine 4-氯-7-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)-1-(2,2,2-三氟乙基)-1H-吲唑-3-胺 | Indazole boronate fragment (4-chloro / 3-amino / N-trifluoroethyl; Suzuki coupling donor) Process note：Boronate ester: moisture-controlled, cold-chain handling; watch protodeboronation impurity and residual palladium | Lenacapavir | |
| 1620056-83-8 | 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid 2-((3bS,4aR)-5,5-二氟-3-(三氟甲基)-3b,4,4a,5-四氢-1H-环丙并[3,4]环戊并[1,2-c]吡唑-1-基)乙酸 | Chiral pyrazole acetic-acid fragment (gem-difluoro + trifluoromethyl cyclopropa-fused cyclopentane core) Process note：Two contiguous stereocentres on a polyfluorinated core — optical purity and isomer separation are the process crux | Lenacapavir | |
| 2189684-54-4 | tert-butyl (S)-(1-(3-bromo-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (S)-(1-(3-溴-6-(3-甲基-3-(甲磺酰基)丁-1-炔-1-基)吡啶-2-基)-2-(3,5-二氟苯基)乙基)氨基甲酸叔丁酯 | Chiral alkynyl sulfone pyridine fragment (Boc-protected amine, bromopyridine, 3,5-difluorophenyl) Process note：Contains an (S)-amine stereocentre and a terminal alkynyl sulfone — requires chiral control and alkyne stability studies | Lenacapavir | |
| 2212021-79-7 | (S)-5-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-N-methyl-N-phenyl-1H-indole-2-carboxamide (S)-5-(2,2-二甲基四氢-2H-吡喃-4-基)-N-甲基-N-苯基-1H-吲哚-2-甲酰胺 | Indole-2-carboxamide fragment bearing the (S)-2,2-dimethyltetrahydro-2H-pyran chiral side chain Process note：Construction and ee control of the chiral side chain dominate cost | Orforglipron | |
| 2212021-83-3 | 5-[(S)-2,2-Dimethyltetrahydro-2H-pyran-4-yl]-1-[(1S,2S)-2-methyl-1-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)cyclopropyl]-1H-indole-2-carboxylic Acid 5-[(S)-2,2-二甲基四氢-2H-吡喃-4-基]-1-[(1S,2S)-2-甲基-1-(5-氧代-4,5-二氢-1,2,4-噁二唑-3-基)环丙基]-1H-吲哚-2-甲酸 | Indole-2-carboxylic acid core fragment with the oxadiazolone-substituted chiral cyclopropane Process note：Two contiguous stereocentres plus an oxadiazolone ring — cyclopropane construction and ring stability are the focus | Orforglipron | |
| 2059155-02-9 | (S)-4-(difluoromethyl)oxazolidin-2-one (S)-4-(二氟甲基)噁唑烷-2-酮 | Chiral difluoromethyl oxazolidinone fragment ((S)-configuration, CF2H) Process note：A small, high-value building block — optical purity and the difluoromethylation step define the process | Inavolisib | |
| 3251-69-2 | 4-Imidazoleacetic acid hydrochloride 4-咪唑乙酸盐酸盐 | Imidazole acetic acid backbone starting material (hydrochloride salt) Process note：A commodity-grade backbone — price and lead time can be locked under an annual framework volume | Osilodrostat |
Common capabilitiesThe same delivery capability backs every campaign project
- ✓Route design and process development: hands-on scale-up experience with fluorinated, chiral, boronate and heterocyclic fragments at partner plants
- ✓Scale continuity: gram-scale validation → hundred-gram → kilogram → commercial, without a route change
- ✓Analytics: chiral ee, related substances, residual solvents, elemental impurities and genotoxic-impurity assessment to ICH conventions
- ✓Registration support: DMF feasibility assessment, starting-material justification, stability study design
- ✓Confidentiality: customer projects run under NDA; no cross-disclosure between plants and end customers
Matching fragment? Send the enquiry
Enquire by CAS number, or send the whole route — we will come back with volumes, lead times and the document set.
Supply scope and compliance note
Most of the target drugs above are originator products still under patent. The intermediates listed here are supplied for research use, and for markets where the patent has expired or a valid licence is in place. The buyer is responsible for confirming patent status and registration requirements in the target market and for the resulting compliance obligations. Third-party brand names and trademarks belong to their respective owners and are referenced here only as a technical cross-reference.
Intermediate lists (CAS and chemical names) are taken from the Division II 2026 Key Projects source sheet. Regulatory and clinical information comes from originator press releases and public FDA material. Fragment roles are neutral descriptions derived from the chemical structure and do not represent the originator patent route. Chinese drug names are common industry transliterations, not official registered names.
Data version 2026-09